78TH SCIENTIFIC SESSIONS PRODUCT THEATER SCHEDULE

Product Theaters, located within the Exhibit Hall, offer informative sessions focusing on products or a single facet of diabetes. Product Theater sessions do not provide continuing education credit. These sessions are intended for health care professionals only with practices relevant to the presented information.

Light refreshments provided by the ADA will be served to the first 300 attendees.

SATURDAY, JUNE 23, 2018

10:15 a.m.-11:00 a.m.
Continuous Glucose Monitoring Reinvented—Introducing the FreeStyle Libre System
Presented by Abbott

Introducing the FreeStyle Libre System. Simple accurate, ¹ and more affordable* continuous glucose monitoring for your patients.

¹ FreeStyle Libre User’s Manual.

* Based on the manufacturer’s list price of the FreeStyle Libre system. The actual cost to you may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

Presenters:  W. Reid Litchfield, MD, FACE, ECNU, FRCP
Desert Endocrinology
Nevada Thyroid Institute
Henderson, NV
Special Guest Speaker

Location:  Product Theater 1 (Booth 173)

10:15 a.m.-11:00 a.m.
Cardiovascular Disease Burden in the U.S. and Clinical Evaluation of VASCEPA® (Icosapent Ethyl)
Presented by Amarin Pharma, Inc.

Hear from an expert about cardiovascular disease burden in the U.S. and clinical evaluation of VASCEPA® (icosapent ethyl). Despite the benefits of LDL-C lowering, many patients on statin therapy remain at risk. In this presentation, new data and perspectives on the role of high triglycerides as a marker of increased cardiovascular risk in patients with statin-controlled LDL-C will be discussed. The clinical development program and safety for pure EPA VASCEPA® will be reviewed.

Presenter:  Eliot A. Brinton, MD
President
Utah Lipid Center
Salt Lake City, UT

Location:  Product Theater 2 (Booth 1472)
Introducing a New Era in Glucose Monitoring—The Eversense® Continuous Glucose Monitoring System

Presented by Senseonics

The world’s first long-term implantable continuous glucose monitoring system.

Based on novel fluorescence technology, Eversense® provides continuous real-time readings up to 3 months with a single sensor. Get a first look at the product technology, which includes a wearable smart transmitter that can be taken on or off and provides discreet vibratory glucose alerts. Learn about the clinical performance resulting in sustained accuracy over the 3-month wear period. During this session, you will hear from clinicians and patients discussing firsthand experience with the technology. At the conclusion of the presentations, there will be a Q&A session. You don’t want to miss this panel of industry experts and current Eversense® users!

Moderator: Steven Edelman, MD
Division of Endocrinology and Metabolism
University of California, San Diego
Founder/Director
Taking Care Of Your Diabetes (TCOYD)
San Diego, CA

Presenters:
E. Lynne Kelley, MD, FACS
Chief Medical Officer
Senseonics, Inc
Germantown, MD

Timothy S. Bailey, MD, FACE, FACP, CPI
President and CEO
AMCR Institute, Inc.
Escondido, CA

Jenine Yager Stone, MSN, FNP-C
Assistant Director, Clinical Research
AMCR Institute, Inc.
Escondido, CA

Tobias Schulte
Eversense® User

Location: Product Theater 3 (Booth 202)
12:15 p.m.-1:15 p.m.
Jardiance® (Empagliflozin) Tablets—Evolving Clinical Development
Presented by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA
This program will discuss recent data from the ongoing Jardiance® clinical development program. The presentation will cover efficacy and safety data, as well as the dosing information for Jardiance®. Attendees will also have the opportunity to ask the faculty questions about the data presented.

Presenters: Leigh Perreault, MD
Associate Professor of Medicine
Division of Endocrinology, Metabolism, and Diabetes
Affiliate Center for Global Health
University of Colorado Anschutz Medical Campus
Associate Professor of Epidemiology
Colorado School of Public Health
Boulder, CO
Pam R. Taub, MD, FACC
Associate Professor of Medicine
University of California, San Diego Health System
San Diego, CA

Location: Product Theater 1 (Booth 173)

12:15 p.m.-1:15 p.m.
The Role of GLP-1 Receptor Agonist Therapy in Type 2 Diabetes Management
Presented by AstraZeneca Pharmaceuticals
This presentation will review the important role of glucagon-like peptide-1 (GLP-1) in physiologic glucose regulation and the mechanism of GLP-1 receptor agonists in addressing the core defects of type 2 diabetes. The clinical efficacy, safety, and potential place in therapy of a once-weekly, GLP-1 receptor agonist, prefilled autoinjector will be discussed. In addition, there will be a live demonstration of the autoinjector.

Presenter: Robert S. Busch, MD
Albany Medical College
Albany, NY

Location: Product Theater 2 (Booth 1472)

12:15 p.m.-1:15 p.m.
Developments in GLP-1 Treatment Options for Adults with Type 2 Diabetes
Presented by Novo Nordisk A/S

Presenter: James R. Gavin III, MD, PhD
Clinical Professor of Medicine
Emory University School of Medicine
Chief Medical Officer
Healing Our Village, Inc.
Atlanta, GA

Location: Product Theater 3 (Booth 202)
2:45 p.m.-3:30 p.m.
Evaluating the Impact of a Safety Outcomes Trial—Incidence of Major Adverse Cardiovascular Events and Clinical Importance of Severe Hypoglycemia for Type 2 Diabetes Patients Requiring a Long-Acting Insulin
Presented by Novo Nordisk A/S

Presenter: Helena W. Rodbard, MD, FACP, MACE
Medical Director
Endocrine and Metabolic Consultants
Rockville, MD

Location: Product Theater 2 (Booth 1472)

2:45 p.m.-3:30 p.m.
Introducing the New Dexcom G6—Simple, Accurate, Effective
Presented by Dexcom

Introduction and review of the new Dexcom G6 Continuous Glucose Monitoring System.
Dexcom G6 CGM technology features accuracy, usability, and product enhancement.
Dexcom G6 pivotal trial data, patient experience, and training best practices.

Presenters: Jake Leach
Senior Vice President, Research and Development
Dexcom
San Diego, CA

Keri Leone, MS, RD, CDE
Senior Director, Global Professional Education
Dexcom
San Diego, CA

R. Paul Wadwa, MD
Associate Professor of Pediatrics
University of Colorado School of Medicine
Director of Telemedicine
Medical Director, Pediatric Clinic,
Barbara Davis Center for Childhood Diabetes
Aurora, CO

Location: Product Theater 3 (Booth 202)
SUNDAY, JUNE 24, 2018

10:15 a.m.-11:00 a.m.
**Praluent® (Alirocumab) Injection—The Time to Treat Is Now**  
*Presented by Sanofi-Regeneron*

**Presenter:** Kenneth Feingold, MD  
Professor of Medicine  
University of California, San Francisco  
San Francisco, CA

**Location:** Product Theater 1 (Booth 173)

10:15 a.m.-11:00 a.m.
**Criticality of LDL-C Lowering in Patients with Diabetes Mellitus**  
*Presented by Amgen*

**Presenter:** Paul S. Jellinger, MD, MACE  
Professor of Clinical Medicine  
University of Miami Miller School of Medicine  
The Center for Diabetes and Endocrine Care  
Ft. Lauderdale, FL

**Location:** Product Theater 2 (Booth 1472)

10:15 a.m.-11:00 a.m.
**The Guardian™ Connect Continuous Glucose Monitoring System—Utilizing Predictive Alerts and Data Backed Insights to Help with Diabetes Management**  
*Presented by Medtronic*

Please join us and learn how predictive alerts and data backed insights of the Guardian™ Connect Smart CGM system can help you and your patients with diabetes management. Presentation will include a system overview, real-world data, case studies, and best practices.

**Presenters:** Timothy S. Bailey, MD, FACE, CPI  
President and CEO  
AMCR Institute, Inc.  
Clinical Associate Professor of Medicine  
University of California, San Diego  
Escondido, CA

Huzefa Neemuchwala, PhD, MBA  
Senior Director, Data and Digital Information  
Medtronic Diabetes  
Northridge, CA

**Location:** Product Theater 3 (Booth 202)
12:30 p.m.-1:30 p.m.
Pneumococcal Disease in Adults Aged <65 Years with Diabetes or Other Select Chronic Conditions
Presented by Merck & Co., Inc.

Describe pneumococcal disease in adults aged <65 years with diabetes or other select chronic conditions. Review CDC recommendations for pneumococcal vaccination in this population. PNEUMOVAX 23—pneumococcal disease vaccine (pneumonia, meningitis, bacteremia).

Location: Product Theater 1 (Booth 173)

12:30 p.m.-1:30 p.m.
Improving Glycemic Control in Type 1 Diabetes—The Role of Insulin-Independent Pathways
Presented by Lexicon Pharmaceuticals and Sanofi

Presenter: Yehuda Handelsman, MD, FACP, FNLA, MACE
Medical Director & Principal Investigator
Metabolic Institute of America
Tarzana, CA

Location: Product Theater 2 (Booth 1472)

12:30 p.m.-1:30 p.m.
Severe Hypertriglyceridemia and Pancreatitis—including Familial Chylomicronemia Syndrome (FCS) in Your Differential Diagnosis
Presented by Akcea Therapeutics

This program provides clinicians with information on Familial Chylomicronemia Syndrome (FCS), a disease in which inherited defects result in the accumulation of chylomicrons in the plasma causing acute pancreatitis and sequelae which can impact daily life including recurrent pain, recurrent acute pancreatitis, and permanent pancreatic damage.

Is a patient like this in your practice?
• Severe, refractory hypertriglyceridemia
  o TG>880 mg/dL
  o Not responsive to standard triglyceride-lowering therapies
• No secondary causes of hypertriglyceridemia
• One or more of:
  o History of pancreatitis
  o History of recurrent abdominal pain without other explainable cause

Objectives for attending clinicians include:
• Differentiate the FCS patient from patients with secondary causes of hypertriglyceridemia
• Appreciate the importance of FCS diagnosis
• Understand the value of connecting FCS patients to educational resources and the FCS patient community

Presenter: Richard L. Dunbar, MD
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Location: Product Theater 3 (Booth 202)
3:00 p.m.-3:45 p.m.
**Basal Insulin Treatment Considerations in Adult Patients with Type 2 Diabetes Mellitus**
*Presented by Sanofi*

**Presenter:** Carol H. Wysham, MD  
Clinical Professor of Medicine  
University of Washington  
Spokane, WA

**Location:** Product Theater 1 (Booth 173)

---

3:00 p.m.-3:45 p.m.
**Closing the Loop with Blood Glucose Meters—Supporting Current Continuous Glucose Monitoring and Future Therapies**
*Presented by Ascensia Diabetes Care*

As diabetes management solutions continue to evolve, for all people with diabetes, the use of Blood Glucose Meters (BGM) play an integral role in supporting other technologies such as Continuous Glucose Monitors (CGM), Flash Glucose Monitors (FGM), Hybrid Closed-Loop System (HCLS) (such as the Medtronic MiniMed™ 670G), and Artificial Pancreas Device Systems (APDS). This session will discuss these technologies and the role of BGM within each.

**Presenter:** Steven Edelman, MD  
Division of Endocrinology and Metabolism  
University of California, San Diego  
Founder/Director  
Taking Care Of Your Diabetes (TCOYD)  
San Diego, CA

**Location:** Product Theater 3 (Booth 202)
MONDAY, JUNE 25, 2018

10:15 a.m.-11:00 a.m.
MiniMed™ 670G System—Increasing Time In Range with Automated Insulin Delivery
Presented by Medtronic
Please join us and learn how the MiniMed™ 670G system has changed the way we are managing time in range for patients with type 1 diabetes. Presentation will include real-world data, case studies, and best practices.

**Presenters:** Jennifer Sherr, MD, PhD
Pediatric Endocrinologist, Associate Professor
Yale School of Medicine
New Haven, CT
Anders L. Carlson, MD
Medical Director
International Diabetes Center at Park Nicollet
Minneapolis, MN

**Location:** Product Theater 1 (Booth 173)

---

10:15 a.m.-11:00 a.m.
Repatha® (Evolocumab)—Putting It into Practice
Presented by Amgen

Join Eliot A. Brinton, MD, FAHA, FNLA, as he conducts an educational presentation on the importance of Repatha® (evolocumab). Hear about his experience with Repatha® and the options available for appropriate patients.

**Presenter:** Eliot A. Brinton, MD, FAHA, FNLA
President
Utah Lipid Center
Salt Lake City, UT

**Location:** Product Theater 2 (Booth 1472)
12:30 p.m.-1:30 p.m.
The Omnipod® DASH™ System—Simplifying Insulin Delivery for Your Patients and Practice
Presented by Insulet Corporation

Learn how the Omnipod® DASH™ Insulin Management System will build on the simplicity and ease-of-use of the existing Omnipod® System platform leveraging its tubeless, waterproof design to address the needs of people with insulin-dependent diabetes. The Omnipod® DASH™ System includes the Pod that will remain unchanged in size with Bluetooth® technology for greater connectivity to the Personal Diabetes Manager (PDM) as well as to the compatible Contour® NEXT One Blood Glucose (BG) Meter. The new, slimmer PDM will feature a color touchscreen interface and will enable discreet insulin delivery with a few finger taps. A new suite of iOS mobile applications will give users and their caregivers quick and easy access to their insulin therapy information on their smartphones. The Omnipod® DASH™ system will also be compatible with Insulet Provided Glooko for easy data upload, improved care team collaboration, and access to meaningful data context which will allow for informed diabetes management decisions. Come to our Product Theater to learn more about the Omnipod® DASH™ System and Insulet’s commitment to reducing the burden of diabetes for health care providers, users, and their caregivers. Caution: Pending 510(k) clearance. Not available for sale in the U.S.

Presenters:  Trang Ly, MBBS, FRACP, PhD
Senior Vice President and Medical Director
Insulet Corporation
Billerica, MA

Daniel DeSalvo, MD
Assistant Professor of Pediatrics of Diabetes & Endocrinology
Baylor College of Medicine/Texas Children’s Hospital
Houston, TX

Location:  Product Theater 1 (Booth 173)

12:30 p.m.-1:30 p.m.
A Treatment Option for Adults with Type 2 Diabetes
Presented by Merck & Co., Inc.

Review select prescribing information for a type 2 diabetes therapeutic option.

Presenter:  Lance Sloan, MD, FACE, FASN
Private Practice
Lufkin, TX

Location:  Product Theater 2 (Booth 1472)